Antirheumatic Agents (DMARDS, non-Biologic)

Non-biologic disease-modifying antirheumatic drugs, commonly categorized in clinical practice and compendia as conventional synthetic DMARDs, are small-molecule immunomodulatory and anti-inflammatory therapies Rather than providing immediate symptom relief like analgesics, these agents modify underlying immune pathways—such as purine or pyrimidine synthesis, cytokine signaling, and antigen processing—to slow radiographic joint damage and reduce systemic inflammation Representative oral agents in...

Non-biologic disease-modifying antirheumatic drugs, commonly categorized in clinical practice and compendia as conventional synthetic DMARDs, are small-molecule immunomodulatory and anti-inflammatory therapies Rather than providing immediate symptom relief like analgesics, these agents modify underlying immune pathways—such as purine or pyrimidine synthesis, cytokine signaling, and antigen processing—to slow radiographic joint damage and reduce systemic inflammation

Rather than providing immediate symptom relief like analgesics, these agents modify underlying immune pathways—such as purine or pyrimidine synthesis, cytokine signaling, and antigen processing—to slow radiographic joint damage and reduce systemic inflammation

Representative oral agents include methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine

They serve as first-line foundational treatments for autoimmune and inflammatory conditions, primarily rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus

They serve as first-line foundational treatments for autoimmune and inflammatory conditions, primarily rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus

They serve as first-line foundational treatments for autoimmune and inflammatory conditions, primarily rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus